<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04421027</url>
  </required_header>
  <id_info>
    <org_study_id>17830</org_study_id>
    <secondary_id>I4V-MC-KHAA</secondary_id>
    <secondary_id>2020-001517-21</secondary_id>
    <nct_id>NCT04421027</nct_id>
  </id_info>
  <brief_title>A Study of Baricitinib (LY3009104) in Participants With COVID-19</brief_title>
  <acronym>COV-BARRIER</acronym>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 3 Study of Baricitinib in Patients With COVID-19 Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The reason for this study is to see if the study drug baricitinib is effective in
      hospitalized participants with COVID-19.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 12, 2020</start_date>
  <completion_date type="Anticipated">September 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants who Die or Require Non-Invasive Ventilation/High-Flow Oxygen or Invasive Mechanical Ventilation (including extracorporeal membrane oxygenation [ECMO])</measure>
    <time_frame>Day 1 to Day 28</time_frame>
    <description>Percentage of Participants who Die or Require Non-Invasive Ventilation/High-Flow Oxygen or Invasive Mechanical Ventilation (including ECMO)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with at Least 1-Point Improvement on NIAID-OS or Live Discharge from Hospital</measure>
    <time_frame>Day 10</time_frame>
    <description>The National Institute of Allergy and Infectious Diseases ordinal scale (NIAID-OS) is an assessment of clinical status. The scale is as follows: Death; Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); Hospitalized, on non-invasive ventilation or high flow oxygen devices; Hospitalized, requiring supplemental oxygen; Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; Not hospitalized, limitation on activities and/or requiring home oxygen; Not hospitalized, no limitations on activities.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Ventilator-Free Days</measure>
    <time_frame>Day 1 to Day 28</time_frame>
    <description>Number of Ventilator-Free Days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Recovery</measure>
    <time_frame>Day 1 to Day 28</time_frame>
    <description>Recovery assessed by the NIAID-OS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Improvement on the NIAID-OS</measure>
    <time_frame>Day 1 to Day 28</time_frame>
    <description>Overall Improvement on the NIAID-OS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Hospitalization</measure>
    <time_frame>Day 1 to Day 28</time_frame>
    <description>Duration of Hospitalization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with a Change in Oxygen Saturation from &lt;94% to ≥94% from Baseline</measure>
    <time_frame>Day 10</time_frame>
    <description>Percentage of Participants with a Change in Oxygen Saturation from &lt;94% to ≥94% from Baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>Day 1 to Day 28</time_frame>
    <description>Mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Stay in the Intensive Care Unit (ICU) in Days</measure>
    <time_frame>Day 1 to Day 28</time_frame>
    <description>Duration of Stay in the ICU in Days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Clinical Deterioration (one-category increase on the NIAID-OS)</measure>
    <time_frame>Day 1 to Day 28</time_frame>
    <description>Time to Clinical Deterioration (one-category increase on the NIAID-OS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Resolution of Fever, in Participants with Fever at Baseline</measure>
    <time_frame>Day 1 to Day 28</time_frame>
    <description>Time to Resolution of Fever, in Participants with Fever at Baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change from Baseline on the National Early Warning Score (NEWS)</measure>
    <time_frame>Baseline, Day 1 to Day 28</time_frame>
    <description>The NEWS is used to detect and report changes in illness severity in participants with acute illness. The score is determined from six physiological parameters readily measured over time in hospitalized participants: Respiration rate; oxygen saturation; temperature; systolic blood pressure; heart (pulse) rate, and level of consciousness</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Definitive Extubation</measure>
    <time_frame>Day 1 to Day 28</time_frame>
    <description>Time to Definitive Extubation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Independence from Non-Invasive Mechanical Ventilation</measure>
    <time_frame>Day 1 to Day 28</time_frame>
    <description>Time to Independence from Non-Invasive Mechanical Ventilation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Independence from Oxygen Therapy in Days</measure>
    <time_frame>Day 1 to Day 28</time_frame>
    <description>Time to Independence from Oxygen Therapy in Days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Days with Supplemental Oxygen Use</measure>
    <time_frame>Day 1 to Day 28</time_frame>
    <description>Number of Days with Supplemental Oxygen Use</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Days of Resting Respiratory Rate &lt;24 Breaths per Minute</measure>
    <time_frame>Day 1 to Day 28</time_frame>
    <description>Number of Days of Resting Respiratory Rate &lt;24 Breaths per Minute</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Baricitinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 milligrams (mg) of baricitinib given orally with background therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo given orally with background therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Baricitinib</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Baricitinib</arm_group_label>
    <other_name>LY3009104</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Hospitalized with coronavirus (SARS-CoV-2) infection, confirmed by polymerase chain
             reaction (PCR) test or other commercial or public health assay in any specimen, as
             documented by either of the following:

               -  PCR positive in sample collected &lt;72 hours prior to randomization; OR

               -  PCR positive in sample collected ≥72 hours prior to randomization (but no more
                  than 14 days prior to randomization), documented inability to obtain a repeat
                  sample (for example, due to lack of testing supplies, limited testing capacity,
                  results taking &gt;24 hours, etc.) AND progressive disease suggestive of ongoing
                  SARS-CoV-2 infection.

          -  Have evidence of pneumonia (SpO2 &lt;94 or PaO2/FiO2 [or SpO2/FiO2] ratio &lt;300 mmHg or
             chest imaging findings consistent with pneumonia), OR have evidence of active COVID
             infection (with clinical symptoms including any of the following: fever, vomiting,
             diarrhea, dry cough, tachypnea defined as respiratory rate &gt;24 breaths/minute).

          -  Have indicators of risk of progression: at least 1 inflammatory markers &gt;upper limit
             of normal (ULN) (C reactive protein [CRP], D dimer, lactate dehydrogenase [LDH],
             ferritin) with at least 1 instance of elevation &gt;ULN within 2 days before study entry.

        Exclusion Criteria:

          -  Are receiving cytotoxic or biologic treatments (such as tumor necrosis factor [TNF]
             inhibitors, anti-interleukin-1 [IL-1], anti-IL-6 [tocilizumab or sarilumab], T-cell or
             B-cell targeted therapies (rituximab), interferon, or Janus kinase (JAK) inhibitors
             for any indication at study entry. Note: A washout period 4 weeks (or 5 half-lives,
             whichever is longer) is required prior to screening.

          -  Have ever received convalescent plasma or intravenous immunoglobulin [IVIg]) for
             COVID-19.

          -  Have received high dose corticosteroids at doses &gt;20 mg per day (or prednisone
             equivalent) administered for ≥14 consecutive days in the month prior to study entry.

          -  Strong inhibitors of OAT3 (such as probenecid) that cannot be discontinued at study
             entry.

          -  Have diagnosis of current active tuberculosis (TB) or, if known, latent TB treated for
             less than 4 weeks with appropriate anti-tuberculosis therapy per local guidelines (by
             history only, no screening tests required).

          -  Suspected serious, active bacterial, fungal, viral, or other infection (besides
             COVID-19) that in the opinion of the investigator could constitute a risk when taking
             investigational product.

          -  Have received any live vaccine within 4 weeks before screening, or intend to receive a
             live vaccine during the study. Note: Use of nonlive (inactivated) vaccinations is
             allowed for all participants.

          -  Require invasive mechanical ventilation, including extracorporeal membrane oxygenation
             (ECMO) at study entry.

          -  Current diagnosis of active malignancy that, in the opinion of the investigator, could
             constitute a risk when taking investigational product.

          -  Have a history of venous thromboembolism (VTE) (deep vein thrombosis [DVT] and
             pulmonary embolism [PE]) within 12 weeks prior to randomization or have a history of
             recurrent (&gt;1) VTE (DVT/PE).

          -  Anticipated discharge from the hospital, or transfer to another hospital (or another
             unit), which is not a study site within 72 hours after study entry.

          -  Have neutropenia (absolute neutrophil count &lt;1000 cells/microliters).

          -  Have lymphopenia (absolute lymphocyte count &lt;200 cells/microliters).

          -  Have alanine aminotransferase (ALT) or aspartate aminotransferase (AST) &gt;5 times ULN.

          -  Estimated glomerular filtration rate (eGFR) (Modification of Diet in Renal Disease
             [MDRD]) &lt;30 milliliter/minute/1.73 meters squared.

          -  Have a known hypersensitivity to baricitinib or any of its excipients.

          -  Are currently enrolled in any other clinical study involving an investigation product
             or any other type of medical research judged not to be scientifically or medically
             compatible with this study. Note: The participant should not be enrolled (start) in
             another clinical trial for the treatment of COVID-19 or SARS CoV-2 through Day 28.

          -  Are pregnant, or intend to become pregnant or breastfeed during the study.

          -  Are using or will use extracorporeal blood purification (EBP) device to remove
             proinflammatory cytokines from the blood such as a cytokine absorption or filtering
             device, for example, CytoSorb®.

          -  Are, in the opinion of the investigator, unlikely to survive for at least 48 hours
             after screening.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-265-4559 or 1-317-615-4559) Mon - Fri 9AM - 5PM Eastern Time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or</last_name>
    <phone>1-317-615-4559</phone>
    <email>ClinicalTrials.gov@lilly.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mercy Gilbert Medical Center</name>
      <address>
        <city>Gilbert</city>
        <state>Arizona</state>
        <zip>85297</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>480-728-3000</phone>
    </contact>
    <investigator>
      <last_name>Brian Tiffany</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Valleywise Health</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85008</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>602-344-5194</phone>
    </contact>
    <investigator>
      <last_name>Mark MacElwee</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St Josephs Hospital and Medical Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85013</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>602-406-2141</phone>
    </contact>
    <investigator>
      <last_name>Omar Gonzalez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hoag Memorial Hospital Presbyterian</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>949-650-9155</phone>
    </contact>
    <investigator>
      <last_name>Philip Robinson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sharp Healthcare</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>858-939-5523</phone>
    </contact>
    <investigator>
      <last_name>Thomas Lawrie</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>San Francisco VA Medical Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>415-221-4810</phone>
    </contact>
    <investigator>
      <last_name>Phyllis Tien</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Holy Cross Hospital Inc.</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33308</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>9542298400</phone>
    </contact>
    <investigator>
      <last_name>Joshua Michael Purow</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Westchester General Hospital</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33155</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>3052645252</phone>
    </contact>
    <investigator>
      <last_name>Jose David Suarez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Grady Health System</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30303</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>404-756-6684</phone>
    </contact>
    <investigator>
      <last_name>Priscilla Pemu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Great Lakes Clinical Trials</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60640</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>773-275-3500</phone>
    </contact>
    <investigator>
      <last_name>Manish Jain</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Community Hospital South</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46227</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>317-621-7724</phone>
    </contact>
    <investigator>
      <last_name>Patrick Milligan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>White Oak Medical Center, Adventist Healthcare</name>
      <address>
        <city>Silver Spring</city>
        <state>Maryland</state>
        <zip>20904</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>240-637-5612</phone>
    </contact>
    <investigator>
      <last_name>Andrew Catanzaro</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>South Shore Hospital</name>
      <address>
        <city>Weymouth</city>
        <state>Massachusetts</state>
        <zip>02190</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>781-624-4369</phone>
    </contact>
    <investigator>
      <last_name>T Ellerin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>313-623-2531</phone>
    </contact>
    <investigator>
      <last_name>Mayur Ramesh</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SUNY Downstate</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>718-270-1847</phone>
    </contact>
    <investigator>
      <last_name>Aaliya Burza</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>OSU Med Intl Med Houston Ctr</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74127</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>918-382-5064</phone>
    </contact>
    <investigator>
      <last_name>Mousumi Som</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>503-494-6994</phone>
    </contact>
    <investigator>
      <last_name>Akram Khan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Temple Univ School of Med</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>215-707-4479</phone>
    </contact>
    <investigator>
      <last_name>Roberto Caricchio</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Swedish Medical Center</name>
      <address>
        <city>Edmonds</city>
        <state>Washington</state>
        <zip>98026</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>206-386-2820</phone>
    </contact>
    <investigator>
      <last_name>Jason Goldman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Swedish Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>206-386-2820</phone>
    </contact>
    <investigator>
      <last_name>Jason Goldman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Swedish Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98122</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>206-386-2820</phone>
    </contact>
    <investigator>
      <last_name>Jason Goldman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Multicare Health System</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>253-403-7251</phone>
    </contact>
    <investigator>
      <last_name>Vinay Malhotra</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Z.G.A.D &quot;Evita Pueblo&quot;</name>
      <address>
        <city>Berazategui</city>
        <state>Buenos Aires</state>
        <zip>1884</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>541149810256</phone>
    </contact>
    <investigator>
      <last_name>Maria Elena Hermida</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sanatorio de la Trinidad Mitre</name>
      <address>
        <city>Caba</city>
        <state>Buenos Aires</state>
        <zip>C1039AAO</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>541149547070</phone>
    </contact>
    <investigator>
      <last_name>Javier David Altclas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fundacion Sanatorio Guemes</name>
      <address>
        <city>Caba</city>
        <state>Buenos Aires</state>
        <zip>C1180AAX</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>5491149598200</phone>
    </contact>
    <investigator>
      <last_name>Anselmo Bertetti</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Interzonal General de Agudos &quot;Eva Peron&quot;</name>
      <address>
        <city>San Martin</city>
        <state>Buenos Aires</state>
        <zip>B1650 NBN</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>541147243000</phone>
    </contact>
    <investigator>
      <last_name>Emilia Silvia Cohen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinica Central S.A.</name>
      <address>
        <city>Villa Regina</city>
        <state>Rio Negro</state>
        <zip>R8336</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>542984461887</phone>
    </contact>
    <investigator>
      <last_name>Horacio Alberto Ariza</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinica Adventista de Belgrano</name>
      <address>
        <city>Ciudad Autonoma Buenos Aires</city>
        <zip>C1430EGF</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>541140141500</phone>
    </contact>
    <investigator>
      <last_name>Marcelo Martin Casas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital San Roque</name>
      <address>
        <city>Cordoba</city>
        <zip>5000</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>3514348772</phone>
    </contact>
    <investigator>
      <last_name>Maria Loenor Parody</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Felício Rocho</name>
      <address>
        <city>Belo Horizonte</city>
        <state>Minas Gerais</state>
        <zip>30110-934</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>553135147195</phone>
    </contact>
    <investigator>
      <last_name>Ana Carolina Procopio Carvalho</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CEPETI Centro de Ensino e Pesquisa em Terapia Intensiva</name>
      <address>
        <city>Curitiba</city>
        <state>Paraná</state>
        <zip>82530-200</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>554133626633</phone>
    </contact>
    <investigator>
      <last_name>Alvaro Rea Neto</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CPCLIN</name>
      <address>
        <city>Natal</city>
        <state>Rio Grande Do Norte</state>
        <zip>59025-050</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>558422260373</phone>
    </contact>
    <investigator>
      <last_name>Kleber Giovanni Luz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de Clinicas de Porto Alegre</name>
      <address>
        <city>Porto Alegre</city>
        <state>RS</state>
        <zip>90035-903</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>555121018634</phone>
    </contact>
    <investigator>
      <last_name>Eduardo Sprinz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pesquisare</name>
      <address>
        <city>Santo Andre</city>
        <state>Sao Paulo</state>
        <zip>09080-110</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>551144273339</phone>
    </contact>
    <investigator>
      <last_name>Rita de Cassia Pellegrini</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Upeclin - Unidade de Pesquisa Clínica da Faculdade de Medicina de Botucatu - UNESP</name>
      <address>
        <city>Botucatu</city>
        <state>São Paulo</state>
        <zip>18618-687</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>1438801171</phone>
    </contact>
    <investigator>
      <last_name>Suzana Erico Tanni MInamoto</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital PUC-CAMPINAS</name>
      <address>
        <city>Campinas</city>
        <state>São Paulo</state>
        <zip>13060-904</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>551933438526</phone>
    </contact>
    <investigator>
      <last_name>Maria Patelli Juliani Souza Lima</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Real e Benemerita Associação Portuguesa de Beneficiencia</name>
      <address>
        <city>São Paulo</city>
        <zip>01323-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>5511981818746</phone>
    </contact>
    <investigator>
      <last_name>Morton Scheinberg</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Alemão Oswaldo Cruz</name>
      <address>
        <city>São Paulo</city>
        <zip>01327-001</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>551135490399</phone>
    </contact>
    <investigator>
      <last_name>Victor Augusto Hamamoto Sato</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universidade Federal de São Paulo - Escola Paulista de Medicina</name>
      <address>
        <city>São Paulo</city>
        <zip>04037-002</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>551155747627</phone>
    </contact>
    <investigator>
      <last_name>Jaquelina Sonoe Ota Arakaki</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Santa Paula</name>
      <address>
        <city>São Paulo</city>
        <zip>04556-100</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>551130408217</phone>
    </contact>
    <investigator>
      <last_name>Cristhieni Rodrigues</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Casa de Saude Santa Marcelina - Centro de Pesquisa Clinica</name>
      <address>
        <city>São Paulo</city>
        <zip>08270-120</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>551120706350</phone>
    </contact>
    <investigator>
      <last_name>Luiz Fernando Degrecci Relvas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Erlangen</name>
      <address>
        <city>Erlangen</city>
        <state>Bayern</state>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>4991318545015</phone>
    </contact>
    <investigator>
      <last_name>Andreas Kremer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum Rechts der Isar der TU München</name>
      <address>
        <city>München</city>
        <state>Bayern</state>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>0049894140?4375</phone>
    </contact>
    <investigator>
      <last_name>Christoph Spinner</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Schleswig-Holstein</name>
      <address>
        <city>Kiel</city>
        <state>Schleswig-Holstein</state>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>+49 431 500 22457</phone>
    </contact>
    <investigator>
      <last_name>Stefan Schreiber</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum Chemnitz gGmbH</name>
      <address>
        <city>Chemnitz</city>
        <zip>09113</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+49 371 333 42790</phone>
    </contact>
    <investigator>
      <last_name>Thomas Grunewald</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Clinicizzato SS Annunziata</name>
      <address>
        <city>Chieti Scalo</city>
        <state>Chieti</state>
        <zip>66013</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>390871541360</phone>
    </contact>
    <investigator>
      <last_name>Francesco Cipollone</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>INMI Lazzaro Spallanzani</name>
      <address>
        <city>Roma</city>
        <state>Rome</state>
        <zip>00149</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>390677204217</phone>
    </contact>
    <investigator>
      <last_name>Emanuele Nicastri</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ASST Fatebenefratelli - Ospedale Luigi Sacco</name>
      <address>
        <city>Milano</city>
        <zip>20157</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>00390250319763</phone>
    </contact>
    <investigator>
      <last_name>Massimo Galli</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Niguarda Ca Granda</name>
      <address>
        <city>Milano</city>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>390264442189</phone>
    </contact>
    <investigator>
      <last_name>Massimo Puoti</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nuovo Ospedale di Prato S. Stefano</name>
      <address>
        <city>Prato</city>
        <zip>59100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>00393408075607</phone>
    </contact>
    <investigator>
      <last_name>Fabrizio Cantini</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yokohama Municipal Citizen's Hospital</name>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <zip>2210855</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>81120023812</phone>
    </contact>
    <investigator>
      <last_name>Natsuo Tachikawa</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Edogawa Medicare Hospital</name>
      <address>
        <city>Edogawa-ku</city>
        <state>Tokyo</state>
        <zip>133 0071</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>+81120023812</phone>
    </contact>
    <investigator>
      <last_name>Motohiko Furuichi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tokyo Medical University Hachioji Medical Center</name>
      <address>
        <city>Hachioji</city>
        <state>Tokyo</state>
        <zip>193-0998</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>81120023812</phone>
    </contact>
    <investigator>
      <last_name>Yuji Hirai</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Edogawa Hospital</name>
      <address>
        <city>Higashi Koiwa Edogawa-ku</city>
        <state>Tokyo</state>
        <zip>133-0052</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>81120023812</phone>
    </contact>
    <investigator>
      <last_name>Shinichi Antoku</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medica Sur</name>
      <address>
        <city>Mexico</city>
        <state>DF</state>
        <zip>14050</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>54247282</phone>
    </contact>
    <investigator>
      <last_name>Luis Enrique Soto Ramirez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional de Cardiologia Ignacio Chavez</name>
      <address>
        <city>Mexico</city>
        <state>DF</state>
        <zip>14080</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>5527270954</phone>
    </contact>
    <investigator>
      <last_name>Gustavo Rojas Velasco</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional de Cancerologia</name>
      <address>
        <city>Mexico City</city>
        <state>FD</state>
        <zip>14080</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>56280447</phone>
    </contact>
    <investigator>
      <last_name>Dora Patricia Cornejo Juarez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ITESM Campus Monterrey</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo Leon</state>
        <zip>64710</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>8113668608</phone>
    </contact>
    <investigator>
      <last_name>Michel Fernando Martínez Resendez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario &quot;Dr. Jose Eleuterio Gonzalez&quot;</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo León</state>
        <zip>64460</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>8181230812</phone>
    </contact>
    <investigator>
      <last_name>Adrian Camacho Ortiz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>City Clinical Hospital #15 named after O.M. Filatov</name>
      <address>
        <city>Moscow</city>
        <zip>111539</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+74953757101</phone>
    </contact>
    <investigator>
      <last_name>Ivan Gordeev</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>First Moscow State Medical University n.a. Sechenov</name>
      <address>
        <city>Moscow</city>
        <zip>119991</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+7 495 248 51 62</phone>
    </contact>
    <investigator>
      <last_name>Dmitry Enikeev</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint-Petersburg City Pokrovskaya Hospital</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>199106</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>78123221041</phone>
    </contact>
    <investigator>
      <last_name>Alexander Vishnevsky</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Txagorritxu</name>
      <address>
        <city>Vitoria</city>
        <state>Alava</state>
        <zip>01009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>647852175</phone>
    </contact>
    <investigator>
      <last_name>Miguel Angel Moran Rodriguez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Infanta Leonor-INTERNAL MED</name>
      <address>
        <city>Madrid</city>
        <zip>28031</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>629564848</phone>
    </contact>
    <investigator>
      <last_name>Miriam Akasbi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>913303274</phone>
    </contact>
    <investigator>
      <last_name>Vicente Estrada</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>651744347</phone>
    </contact>
    <investigator>
      <last_name>Maria Luisa Briones</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Cornwall Hospital</name>
      <address>
        <city>Truro</city>
        <state>Cornwall</state>
        <zip>TR1 3LJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>441872253849</phone>
    </contact>
    <investigator>
      <last_name>David Hutchinson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Free Hospital</name>
      <address>
        <city>London</city>
        <state>Hampstead</state>
        <zip>NW3 2QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>442085395522</phone>
    </contact>
    <investigator>
      <last_name>Hasan Tahir</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. George'S Healthcare Nhs Trust</name>
      <address>
        <city>London</city>
        <zip>SW17 0QT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>0208 725 0042</phone>
    </contact>
    <investigator>
      <last_name>Nidhi Sofat</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Brazil</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Mexico</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trials.lillytrialguide.com/en-US/trial/1QT4STirLDGakzCVTBX2Rv?conditionId=18SDoTG6slClCGmk7GrUEU</url>
    <description>A Study of Baricitinib (LY3009104) in Participants With COVID-19 (COV-BARRIER)</description>
  </link>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>June 5, 2020</study_first_submitted>
  <study_first_submitted_qc>June 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 9, 2020</study_first_posted>
  <last_update_submitted>July 20, 2020</last_update_submitted>
  <last_update_submitted_qc>July 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>coronavirus</keyword>
  <keyword>coronavirus infection</keyword>
  <keyword>safety</keyword>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting</ipd_time_frame>
    <ipd_access_criteria>Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting</ipd_access_criteria>
    <ipd_url>http://vivli.org/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

